Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Department for Medical Innovation and Translational Medical Science, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
J Gastroenterol Hepatol. 2019 Jul;34(7):1193-1200. doi: 10.1111/jgh.14532. Epub 2018 Nov 22.
Daikenchuto, a traditional Japanese herbal medicine, has been reported to exhibit anti-inflammatory effects against intestinal inflammation. However, whether daikenchuto has a therapeutic effect against intestinal mucosal injuries remains unclear. Thus, the aim of this study was to determine the effect of daikenchuto on intestinal mucosal healing.
Colitis was induced in male Wistar rats by using trinitrobenzenesulfonic acid. Daikenchuto (900 mg/kg/day) was administered for 7 days after the induction of colitis. Thereafter, intestinal mucosal injuries were evaluated by determining the colonic epithelial regeneration ratio ([area of epithelial regeneration/area of ulcer] × 100). Restoration of rat intestinal epithelial cells treated with daikenchuto and its constituent herbs (Zanthoxylum fruit, processed ginger, and ginseng) and ginsenoside Rb1, which is a ginseng ingredient, was evaluated using a wound-healing assay.
The colon epithelial regeneration ratio in the daikenchuto-treated rats was significantly higher than that in the control rats. Daikenchuto, ginseng, and ginsenoside Rb1 enhanced wound healing, and the ginsenoside Rb1-induced enhancement was inhibited by extracellular signal-regulated kinase and Rho inhibitors.
Daikenchuto and its constituent, ginsenoside Rb1, promoted wound healing. Because mucosal healing is one of the most important therapeutic targets in patients with inflammatory bowel disease, ginsenoside Rb1 may be a novel therapeutic agent against intestinal mucosal damage such as that occurring in intestinal bowel disease.
大建中汤是一种传统的日本草药,据报道具有抗炎作用,可以缓解肠道炎症。然而,大建中汤是否对肠道黏膜损伤具有治疗作用尚不清楚。因此,本研究旨在确定大建中汤对肠道黏膜愈合的影响。
采用三硝基苯磺酸诱导雄性 Wistar 大鼠结肠炎。在诱导结肠炎后,给予大建中汤(900mg/kg/天)治疗 7 天。此后,通过测定结肠上皮再生率([上皮再生面积/溃疡面积]×100)来评估肠道黏膜损伤。采用划痕实验评估大建中汤及其组成草药(花椒、炮姜、人参)和人参成分人参皂苷 Rb1 处理的大鼠肠道上皮细胞的恢复情况。
大建中汤治疗组大鼠的结肠上皮再生率明显高于对照组。大建中汤、人参和人参皂苷 Rb1 均能促进伤口愈合,而 Rho 抑制剂和细胞外信号调节激酶抑制剂可抑制人参皂苷 Rb1 诱导的增强作用。
大建中汤及其成分人参皂苷 Rb1 可促进伤口愈合。由于黏膜愈合是炎症性肠病患者最重要的治疗靶点之一,因此人参皂苷 Rb1 可能是一种治疗肠道黏膜损伤的新型药物,例如发生在炎症性肠病中的肠道黏膜损伤。